GLP-1 Peptide Atlas, by Delfa

CompletedPhase 2Results posted

Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients With Type 2 Diabetes Treated Only With Lifestyle Interventions

Lead sponsor

Eli Lilly and Company

Asset

Dulaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

167

actual

Study population

Type 2 diabetes

Key I/E criterion

•BMI 23-40

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00791479

Org study ID12565

Secondary IDCTRI/2009/091/000105India

Secondary IDH9X-MC-GBCKEli Lilly and Company

Timeline

Milestones

Study first posted2008-11-14estimated

Last update posted2014-12-10estimated

Results first posted2014-12-10estimated

Study start2008-12 (month precision)

Primary completion2010-01actual (month precision)

Study completion2010-01actual (month precision)

Assets

Investigational agents

Dulaglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Diabetes mellitus, type 2

•Treatment regimens: diet and exercise only or are taking metformin as monotherapy and are willing to discontinue this medication

•Have completed at least 8 weeks of wash-out prior to randomization (if on metformin therapy at screening)

•Have a qualifying glycosylated hemoglobin (HbA1c) value, as determined by the central laboratory: at screening (for diet and exercise only ≥7.0% to ≤9.5%; for metformin monotherapy >6.5% to ≤9.0%) and at time of randomization for all participants ≥6.5% to ≤9.5%

•Females of childbearing potential must test negative for pregnancy and agree to use a reliable birth control method

•Have a body mass index (BMI) between 23 and 40 kilograms/meter squared (kg/m^2), inclusive, for participants who are native to, and reside in, South and/or East Asia; all other participants must have a BMI between 25 and 40 kg/m^2, inclusive.

•Stable weight for 3 months prior to screening

Exclusion criteria

•Diabetes mellitus, type 1

•Taking any glucose-lowering oral agents other than metformin within 3 months prior to screening

•Use of glucagon-like peptide-1 (GLP-1) analog (for example, exenatide) within 6 months prior to screening or being treated within insulin (with the exception of short-term management of acute conditions that occurred more than 3 months immediately prior to screening)

•Use of medications (prescription or over-the counter) to promote weight loss

•Chronic (>2 weeks) use of systemic glucocorticoid therapy

•Gastric emptying abnormality, history of bariatric surgery or chronic use of drugs that affect gastrointestinal motility

•Use of central nervous system (CNS) stimulant (for example, Ritalin-sustained release [SR])

•Cardiovascular event within 6 months prior to screening

•Poorly controlled hypertension (determined by a mean seated systolic blood pressure (BP) ≥160 millimeters of mercury (mmHg) or mean seated diastolic BP ≥95 mmHg at screening or randomization)

•Electrocardiogram (ECG) reading considered outside the normal limits by the investigator and relevant for interpretation or indicating cardiac disease

•Liver disease, hepatitis, chronic hepatitis, or alanine transaminase levels >3.0 times upper limit of normal

•Clinical signs or symptoms of pancreatitis or history of chronic or acute pancreatitis at time of screening

•Amylase ≥3 times the upper limit of normal and/or lipase ≥2 times upper limit of normal which are determined by central labs at the time of screening

•Serum creatinine ≥1.5 milligrams per deciliter (mg/dL) for men or ≥1.4 mg/dL for women or a creatinine clearance <60 milliliter (mL)/minute which are determined by central labs at the time of screening

•Uncontrolled diabetes (defined as 2 or more episode of hyperosmolar state requiring hospitalization in the 6 months prior to screening)

•Significant active, uncontrolled endocrine or autoimmune abnormality

•History of a transplanted organ (corneal transplants are allowed)

•Active or untreated malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years

•Have any other condition, in the opinion of the investigator, that may preclude the participant from following or completing the protocol

•Investigator site personnel directly affiliated with this study and/or their immediate families (spouse, parent, child, or sibling, whether biological or legally adopted)

•Sponsor employees

•Received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry

•Participated in an interventional medical, surgical, or pharmaceutical study within 30 days prior to entry into the study

•Have previously completed or withdrawn from this study after providing informed consent

Endpoints (34)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Safety / tolerability / PK

Cardiometabolic biomarkers

Weight & body composition

2 endpoints

Secondary/registry result

Change From Baseline in Body Weight

Time frame:Baseline, 12 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kilogram (kg)	95% CI
0.1 Milligrams (mg) LY2189265	-0.19	—
0.5 Milligrams (mg) LY2189265	-0.34	—
1.0 Milligrams (mg) LY2189265	-1.11	—
1.5 Milligrams (mg) LY2189265	-1.49	—
Placebo	-1.38	—

p0.969Mixed Models Analysis

Test of log linear dose response with placebo.

p0.009Mixed Models Analysis

Test of log linear dose response without placebo.

Mean Difference (Final Values)1.19p0.140Mixed Models Analysis

Mean Difference (Final Values)1.04p0.247Mixed Models Analysis

Mean Difference (Final Values)0.27p0.975Mixed Models Analysis

Mean Difference (Final Values)-0.11p1.00Mixed Models Analysis

Secondary/protocol endpoint

Change From Baseline in Body Weight

Time frame:Baseline, 12 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

14 endpoints

Primary/registry result

Change From Baseline in Glycosylated Hemoglobin (HbA1c)

Time frame:Baseline, 12 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (least_squares_mean), percentage of glycosylated hemoglobin	95% CI
0.1 Milligrams (mg) LY2189265	-0.37	—
0.5 Milligrams (mg) LY2189265	-0.89	—
1.0 Milligrams (mg) LY2189265	-1.03	—
1.5 Milligrams (mg) LY2189265	-1.04	—
Placebo	0.01	—

p<0.001Mixed Models Analysis

Test of log linear dose response with placebo.

p<0.001Mixed Models Analysis

Test of log linear dose response without placebo.

Mean Difference (Final Values)-0.37p0.069Mixed Models Analysis

Mean Difference (Final Values)-0.89p<0.001Mixed Models Analysis

Mean Difference (Final Values)-1.04p<0.001Mixed Models Analysis

Primary/protocol endpoint

Change From Baseline in Glycosylated Hemoglobin (HbA1c)

Time frame:Baseline, 12 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/registry result

Change From Baseline in Glycosylated Hemoglobin (HbA1c)

Time frame:Baseline, 4 weeks, 8 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (least_squares_mean), percentage of glycosylated hemoglobin	95% CI
0.1 Milligrams (mg) LY2189265Week 4 (n=35, n=34, n=34, n=25, n=29)	-0.28	—
Week 8 (n=35, n=30, n=33, n=24, n=28)	-0.33	—
0.5 Milligrams (mg) LY2189265Week 4 (n=35, n=34, n=34, n=25, n=29)	-0.51	—
Week 8 (n=35, n=30, n=33, n=24, n=28)	-0.74	—
1.0 Milligrams (mg) LY2189265Week 4 (n=35, n=34, n=34, n=25, n=29)	-0.46	—
Week 8 (n=35, n=30, n=33, n=24, n=28)	-0.78	—
1.5 Milligrams (mg) LY2189265Week 4 (n=35, n=34, n=34, n=25, n=29)	-0.53	—
Week 8 (n=35, n=30, n=33, n=24, n=28)	-0.90	—
PlaceboWeek 4 (n=35, n=34, n=34, n=25, n=29)	-0.01	—
Week 8 (n=35, n=30, n=33, n=24, n=28)	-0.00	—

p<0.001Mixed Models Analysis

Test of log linear dose response with placebo.

p0.023Mixed Models Analysis

Test of log linear dose response without placebo.

p<0.001Mixed Models Analysis

Test of log linear dose response with placebo.

p<0.001Mixed Models Analysis

Test of log linear dose response without placebo.

Secondary/registry result

Change From Baseline in Fasting Blood Glucose

Time frame:Baseline, 12 weeks

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (least_squares_mean), milligrams per deciliter (mg/dL)	95% CI
0.1 Milligrams (mg) LY2189265	-11.59	—
0.5 Milligrams (mg) LY2189265	-30.31	—
1.0 Milligrams (mg) LY2189265	-33.73	—
1.5 Milligrams (mg) LY2189265	-37.49	—
Placebo	-3.78	—

p<0.001Mixed Models Analysis

Test of log linear dose response with placebo.

p<0.001Mixed Models Analysis

Test of log linear dose response without placebo.

Mean Difference (Final Values)-7.81p0.456Mixed Models Analysis

Mean Difference (Final Values)-26.53p<0.001Mixed Models Analysis

Mean Difference (Final Values)-29.96p<0.001Mixed Models Analysis

Mean Difference (Final Values)-33.71p<0.001Mixed Models Analysis

Secondary/registry result

Percentage of Participants Who Achieve Glycosylated Hemoglobin (HbA1c) <7% or ≤6.5%

Time frame:12 weeks

HbA1c <7.0% achievement

threshold achievement, improvement

componentsHbA1c <7.0% achievement, HbA1c <6.5% achievement

LOINC 4548-4

Posted result

Group	Value (number), percentage of participants	95% CI
0.1 Milligrams (mg) LY2189265HbA1c levels <7.0% (n=34, n=30, n=32, n=21, n=28)	47.1	—
HbA1c levels ≤6.5% (n=34, n=30, n=32, n=21, n=28)	14.7	—
0.5 Milligrams (mg) LY2189265HbA1c levels <7.0% (n=34, n=30, n=32, n=21, n=28)	73.3	—
HbA1c levels ≤6.5% (n=34, n=30, n=32, n=21, n=28)	53.3	—
1.0 Milligrams (mg) LY2189265HbA1c levels <7.0% (n=34, n=30, n=32, n=21, n=28)	75.0	—
HbA1c levels ≤6.5% (n=34, n=30, n=32, n=21, n=28)	50.0	—
1.5 Milligrams (mg) LY2189265HbA1c levels <7.0% (n=34, n=30, n=32, n=21, n=28)	71.4	—
HbA1c levels ≤6.5% (n=34, n=30, n=32, n=21, n=28)	52.4	—
PlaceboHbA1c levels <7.0% (n=34, n=30, n=32, n=21, n=28)	21.4	—
HbA1c levels ≤6.5% (n=34, n=30, n=32, n=21, n=28)	7.1	—

p<0.001Cochran-Armitage trend test

Secondary/registry result

Change From Baseline in Daily Mean Blood Glucose Values From the 7-point Self Monitored Blood Glucose (SMBG) Profiles

Time frame:Baseline, 12 weeks

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), milligrams per deciliter (mg/dL)	95% CI
0.1 Milligrams (mg) LY2189265	-15.77	—
0.5 Milligrams (mg) LY2189265	-32.21	—
1.0 Milligrams (mg) LY2189265	-42.46	—
1.5 Milligrams (mg) LY2189265	-44.79	—
Placebo	-6.12	—

p<0.001Mixed Models Analysis

Test of log linear dose response with placebo.

p<0.001Mixed Models Analysis

Test of log linear dose response without placebo.

Mean Difference (Final Values)-9.65p0.378Mixed Models Analysis

Mean Difference (Final Values)-26.09p<0.001Mixed Models Analysis

Mean Difference (Final Values)-36.34p<0.001Mixed Models Analysis

Mean Difference (Final Values)-38.67p<0.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in Beta-cell Function (HOMA2-%B)

Time frame:Baseline, 12 weeks

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), percentage of HOMA2-%B	95% CI
0.1 Milligrams (mg) LY2189265	13.18	—
0.5 Milligrams (mg) LY2189265	31.66	—
1.0 Milligrams (mg) LY2189265	39.04	—
1.5 Milligrams (mg) LY2189265	29.29	—
Placebo	-2.06	—

p<0.001Mixed Models Analysis

Test of log linear dose response with placebo.

p0.036Mixed Models Analysis

Test of log linear dose response without placebo.

Secondary/registry result

Change From Baseline in Insulin Sensitivity (HOMA2-%S)

Time frame:Baseline, 12 weeks

HOMA-IR (insulin sensitivity)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), percentage of HOMA2-%S	95% CI
0.1 Milligrams (mg) LY2189265	-2.41	—
0.5 Milligrams (mg) LY2189265	6.10	—
1.0 Milligrams (mg) LY2189265	-4.80	—
1.5 Milligrams (mg) LY2189265	12.98	—
Placebo	0.58	—

p0.450Mixed Models Analysis

Test of log linear dose response with placebo.

p0.329Mixed Models Analysis

Test of log linear dose response without placebo.

Secondary/protocol endpoint

Change From Baseline in Glycosylated Hemoglobin (HbA1c)

Time frame:Baseline, 4 weeks, 8 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change From Baseline in Fasting Blood Glucose

Time frame:Baseline, 12 weeks

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Percentage of Participants Who Achieve Glycosylated Hemoglobin (HbA1c) <7% or ≤6.5%

Time frame:12 weeks

threshold achievement, improvement

componentsHbA1c <7.0% achievement, HbA1c <6.5% achievement

LOINC 4548-4

Secondary/protocol endpoint

Change From Baseline in Daily Mean Blood Glucose Values From the 7-point Self Monitored Blood Glucose (SMBG) Profiles

Time frame:Baseline, 12 weeks

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Beta-cell Function (HOMA2-%B)

Time frame:Baseline, 12 weeks

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Insulin Sensitivity (HOMA2-%S)

Time frame:Baseline, 12 weeks

HOMA-IR (insulin sensitivity)

change from baseline, improvement

Cardiometabolic biomarkers

6 endpoints

Secondary/registry result

Change From Baseline in Electrocardiograms (ECGs) - Heart Rate

Time frame:Baseline, 12 weeks

Heart rate, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), beats per minute (bpm)	95% CI
0.1 Milligrams (mg) LY2189265	1.38	—
0.5 Milligrams (mg) LY2189265	1.16	—
1.0 Milligrams (mg) LY2189265	1.88	—
1.5 Milligrams (mg) LY2189265	4.18	—
Placebo	0.67	—

Secondary/registry result

Change From Baseline in Pulse Rate

Time frame:Baseline, 12 weeks

Heart rate, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), beats per minute (bpm)	95% CI
0.1 Milligrams (mg) LY2189265	0.19	—
0.5 Milligrams (mg) LY2189265	0.25	—
1.0 Milligrams (mg) LY2189265	1.02	—
1.5 Milligrams (mg) LY2189265	1.34	—
Placebo	1.29	—

Secondary/registry result

Change From Baseline in Blood Pressure (BP)

Time frame:Baseline, 12 weeks

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), millimeters of mercury (mmHg)	95% CI
0.1 Milligrams (mg) LY2189265Sitting Systolic Blood Pressure	-2.21	—
Sitting Diastolic Blood Pressure	-0.24	—
0.5 Milligrams (mg) LY2189265Sitting Systolic Blood Pressure	0.51	—
Sitting Diastolic Blood Pressure	0.59	—
1.0 Milligrams (mg) LY2189265Sitting Systolic Blood Pressure	-2.57	—
Sitting Diastolic Blood Pressure	0.42	—
1.5 Milligrams (mg) LY2189265Sitting Systolic Blood Pressure	1.88	—
Sitting Diastolic Blood Pressure	1.56	—
PlaceboSitting Systolic Blood Pressure	-0.68	—
Sitting Diastolic Blood Pressure	1.07	—

Secondary/protocol endpoint

Change From Baseline in Electrocardiograms (ECGs) - Heart Rate

Time frame:Baseline, 12 weeks

Heart rate, change

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Pulse Rate

Time frame:Baseline, 12 weeks

Heart rate, change

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Blood Pressure (BP)

Time frame:Baseline, 12 weeks

change from baseline, improvement

Safety / tolerability / PK

12 endpoints

Secondary/registry result/low confidence

Change From Baseline in Electrocardiograms (ECGs) - Fridericia-corrected QT (QTcF) and PR Interval

Time frame:Baseline, 12 weeks

change from baseline, descriptive

componentsqtc f change, pr interval change

Posted result

Group	Value (least_squares_mean), millisecond (msec)	95% CI
0.1 Milligrams (mg) LY2189265Fridericia-corrected QT (QTcF) Interval	1.34	—
PR Interval	3.22	—
0.5 Milligrams (mg) LY2189265Fridericia-corrected QT (QTcF) Interval	-1.18	—
PR Interval	4.57	—
1.0 Milligrams (mg) LY2189265Fridericia-corrected QT (QTcF) Interval	4.56	—
PR Interval	-0.55	—
1.5 Milligrams (mg) LY2189265Fridericia-corrected QT (QTcF) Interval	-0.63	—
PR Interval	2.83	—
PlaceboFridericia-corrected QT (QTcF) Interval	0.70	—
PR Interval	-0.89	—

Secondary/registry result

Number of Participants With Self-reported Hypoglycemic Events

Time frame:Baseline through 12 weeks

Documented hypoglycemia

event count, event

Posted result

Group	Value (number), participants	95% CI
0.1 Milligrams (mg) LY2189265Documented Symptomatic	0	—
Asymptomatic	1	—
Severe	0	—
Nocturnal	1	—
0.5 Milligrams (mg) LY2189265Documented Symptomatic	2	—
Asymptomatic	0	—
Severe	0	—
Nocturnal	2	—
1.0 Milligrams (mg) LY2189265Documented Symptomatic	2	—
Asymptomatic	0	—
Severe	0	—
Nocturnal	1	—
1.5 Milligrams (mg) LY2189265Documented Symptomatic	3	—
Asymptomatic	0	—
Severe	0	—
Nocturnal	2	—
PlaceboDocumented Symptomatic	0	—
Asymptomatic	0	—
Severe	0	—
Nocturnal	0	—

Secondary/registry result

Rate of Self-reported Hypoglycemic Events

Time frame:Baseline through 12 weeks

Documented hypoglycemia

event count, event

Posted result

Group	Value (least_squares_mean), Events per participant per year	95% CI
0.1 Milligrams (mg) LY2189265Documented Symptomatic Hypoglycemic Rate	-0.08	—
Asymptomatic Hypoglycemic Rate	0.19	—
Severe Hypoglycemic Rate	0	—
Nocturnal Hypoglycemic Rate	0.20	—
0.5 Milligrams (mg) LY2189265Documented Symptomatic Hypoglycemic Rate	0.25	—
Asymptomatic Hypoglycemic Rate	-0.01	—
Severe Hypoglycemic Rate	0	—
Nocturnal Hypoglycemic Rate	0.16	—
1.0 Milligrams (mg) LY2189265Documented Symptomatic Hypoglycemic Rate	1.68	—
Asymptomatic Hypoglycemic Rate	-0.01	—
Severe Hypoglycemic Rate	0	—
Nocturnal Hypoglycemic Rate	1.21	—
1.5 Milligrams (mg) LY2189265Documented Symptomatic Hypoglycemic Rate	0.61	—
Asymptomatic Hypoglycemic Rate	0.02	—
Severe Hypoglycemic Rate	0	—
Nocturnal Hypoglycemic Rate	0.21	—
PlaceboDocumented Symptomatic Hypoglycemic Rate	-0.09	—
Asymptomatic Hypoglycemic Rate	0.01	—
Severe Hypoglycemic Rate	0	—
Nocturnal Hypoglycemic Rate	-0.08	—

Secondary/registry result

Treatment Emergent Adverse Events

Time frame:Baseline through 12 weeks

Treatment-emergent AEs (any)

event count, event

Posted result

Group	Value (number), participants	95% CI
0.1 Milligrams (mg) LY2189265	21	—
0.5 Milligrams (mg) LY2189265	17	—
1.0 Milligrams (mg) LY2189265	20	—
1.5 Milligrams (mg) LY2189265	18	—
3.0 Milligrams (mg) LY2189265	1	—
Placebo	18	—

Secondary/registry result

Antibody Production and Effects to LY2189265

Time frame:Baseline, 4 weeks, 12 weeks, 16 weeks

Immunogenicity (ADA)

threshold achievement, event

Posted result

Group	Value (number), participants	95% CI
0.1 Milligrams (mg) LY2189265Week 4	0	—
Week 12	0	—
Week 16	0	—
0.5 Milligrams (mg) LY2189265Week 4	0	—
Week 12	0	—
Week 16	0	—
1.0 Milligrams (mg) LY2189265Week 4	1	—
Week 12	0	—
Week 16	0	—
1.5 Milligrams (mg) LY2189265Week 4	0	—
Week 12	0	—
Week 16	0	—
PlaceboWeek 4	0	—
Week 12	0	—
Week 16	0	—

Secondary/registry result

Collection and Evaluation of Plasma Levels (Pharmacokinetics [PK]) of LY2189265

Time frame:4 weeks, 8 weeks, 12 weeks

AUC₀–∞

concentration, descriptive

Posted result

Group	Value (mean), nanogramshour/milliliter (ngh/mL)	95% CI
0.1 Milligrams (mg) LY2189265	2294	—
0.5 Milligrams (mg) LY2189265	6650	—
1.0 Milligrams (mg) LY2189265	11671	—
1.5 Milligrams (mg) LY2189265	16649	—
3.0 Milligrams (mg) LY2189265	31538	—

Secondary/protocol endpoint

Change From Baseline in Electrocardiograms (ECGs) - Fridericia-corrected QT (QTcF) and PR Interval

Time frame:Baseline, 12 weeks

change from baseline, descriptive

componentsqtcF change, pr interval change

Secondary/protocol endpoint

Number of Participants With Self-reported Hypoglycemic Events

Time frame:Baseline through 12 weeks

Documented hypoglycemia

event count, event

Secondary/protocol endpoint

Rate of Self-reported Hypoglycemic Events

Time frame:Baseline through 12 weeks

Documented hypoglycemia

event count, event

Secondary/protocol endpoint

Treatment Emergent Adverse Events

Time frame:Baseline through 12 weeks

Treatment-emergent AEs (any)

event count, event

Secondary/protocol endpoint

Antibody Production and Effects to LY2189265

Time frame:Baseline, 4 weeks, 12 weeks, 16 weeks

Immunogenicity (ADA)

threshold achievement, event

Secondary/protocol endpoint

Collection and Evaluation of Plasma Levels (Pharmacokinetics [PK]) of LY2189265

Time frame:4 weeks, 8 weeks, 12 weeks

AUC₀–∞

concentration, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.
Diabetic medicine : a journal of the British Diabetic Association2012 Oct (month)PMID22804250doi:10.1111/j.1464-5491.2012.03745.xvia CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.